CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The ITHEMYC project aims to develop innovative adjunctive immunotherapies for tuberculosis by combining existing antibiotic treatments with new therapies. The project focuses on improving treatment outcomes, reducing duration and side effects, and controlling drug-resistant strains through a multidisciplinary approach…
Tuberculosis (TB) remains the leading cause of death due to a single pathogen, Mycobacterium tuberculosis (Mtb; except in 2020-2022, when it was surpassed by the COVID-19 pandemic), with 1.5 million deaths in 2020.
The lengthy TB treatment and the numerous adverse events contribute to poor medical adherence and development of antibiotic resistant strains.
Thus, novel therapeutic modalities are urgently needed to shorten treatment duration, improve outcomes and control the emergence of drug resis…
STICHTING TUBERCULOSIS VACCINE INITIATIVE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Tres Cantos
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
France, TOULOUSE
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United States, NEW YORK
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
